These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18927290)

  • 1. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947.
    Libertini S; Iacuzzo I; Perruolo G; Scala S; Ieranò C; Franco R; Hallden G; Portella G
    Clin Cancer Res; 2008 Oct; 14(20):6505-14. PubMed ID: 18927290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947.
    Libertini S; Abagnale A; Passaro C; Botta G; Barbato S; Chieffi P; Portella G
    Endocr Relat Cancer; 2011 Feb; 18(1):129-41. PubMed ID: 21071467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ionizing radiation enhances dl922-947-mediated cell death of anaplastic thyroid carcinoma cells.
    Passaro C; Abagnale A; Libertini S; Volpe M; Botta G; Cella L; Pacelli R; Halldèn G; Gillespie D; Portella G
    Endocr Relat Cancer; 2013 Oct; 20(5):633-47. PubMed ID: 23839822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells.
    Libertini S; Iacuzzo I; Ferraro A; Vitale M; Bifulco M; Fusco A; Portella G
    Endocrinology; 2007 Nov; 148(11):5186-94. PubMed ID: 17690162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.
    Passaro C; Borriello F; Vastolo V; Di Somma S; Scamardella E; Gigantino V; Franco R; Marone G; Portella G
    Oncotarget; 2016 Jan; 7(2):1500-15. PubMed ID: 26625205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma.
    Passaro C; Volpe M; Botta G; Scamardella E; Perruolo G; Gillespie D; Libertini S; Portella G
    Mol Oncol; 2015 Jan; 9(1):78-92. PubMed ID: 25139258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers.
    Deguchi T; Shikano T; Kasuya H; Nawa A; Fujiwara S; Takeda S; Gewen T; Sahin TT; Yamada S; Kanzaki A; Yamamura K; Fujii T; Sugimoto H; Nomoto S; Fukuda S; Nishikawa Y; Kodera Y; Nakao A
    Hepatogastroenterology; 2012 Sep; 59(118):1844-50. PubMed ID: 22172413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma.
    Prichard CN; Kim S; Yazici YD; Doan DD; Jasser SA; Mandal M; Myers JN
    Laryngoscope; 2007 Apr; 117(4):674-9. PubMed ID: 17429874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
    Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
    J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of autophagy enhances the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo.
    Botta G; Passaro C; Libertini S; Abagnale A; Barbato S; Maione AS; Hallden G; Beguinot F; Formisano P; Portella G
    Hum Gene Ther; 2012 Jun; 23(6):623-34. PubMed ID: 22475378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.
    Salaun PY; Bodet-Milin C; Frampas E; Oudoux A; Saï-Maurel C; Faivre-Chauvet A; Barbet J; Paris F; Kraeber-Bodéré F
    Cancer; 2010 Feb; 116(4 Suppl):1053-8. PubMed ID: 20127950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
    Radhakrishnan S; Miranda E; Ekblad M; Holford A; Pizarro MT; Lemoine NR; Halldén G
    Hum Gene Ther; 2010 Oct; 21(10):1311-25. PubMed ID: 20497039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.
    Guse K; Ranki T; Ala-Opas M; Bono P; Särkioja M; Rajecki M; Kanerva A; Hakkarainen T; Hemminki A
    Mol Cancer Ther; 2007 Oct; 6(10):2728-36. PubMed ID: 17938266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin.
    Lockley M; Fernandez M; Wang Y; Li NF; Conroy S; Lemoine N; McNeish I
    Cancer Res; 2006 Jan; 66(2):989-98. PubMed ID: 16424034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.
    Ramesh N; Ge Y; Ennist DL; Zhu M; Mina M; Ganesh S; Reddy PS; Yu DC
    Clin Cancer Res; 2006 Jan; 12(1):305-13. PubMed ID: 16397056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.